CD11c( ) Dendritic Cells and B Cells Contribute to the Tumoricidal Activity of Anti-DR5 Antibody Therapy in Established Tumors
Nicole M Haynes, Edwin D Hawkins, Ming Li, Nicole M McLaughlin, Guenther J Haemmerling, Reto Schwendener, Astar Winoto, Allen Wensky, Hideo Yagita, Kazuyoshi Takeda, Michael H Kershaw, Phillip K Darcy, Mark J Smyth
JOURNAL OF IMMUNOLOGY | AMER ASSOC IMMUNOLOGISTS | Published : 2010
The selective targeting of the tumor-associated death-inducing receptors DR4 and DR5 with agonistic mAbs has demonstrated preclinical and clinical antitumor activity. However, the cellular and molecular mechanisms contributing to this efficacy remain poorly understood. In this study, using the first described C57BL/6 (B6) TRAIL-sensitive experimental tumor models, we have characterized the innate and adaptive immune components involved in the primary rejection phase of an anti-mouse DR5 (mDR5) mAb, MD5-1 in established MC38 colon adenocarcinomas. FcR mediated cross-linking of MD5-1 significantly inhibited the growth of MC38 colon adenocarcinomas through the induction of TRAIL-R-dependent tum..View full abstract
Awarded by Grants-in-Aid for Scientific Research
This work was supported by a National Health and Medical Research Council of Australia program grant, a Cancer Council of Victoria project grant, and a Cure Cancer Australia grant. M.J.S. was supported by a National Health and Medical Research Council of Australia fellowship. N.M.H was supported in part by a National Health and Medical Research Council of Australia C.J. Martin fellowship.